ArticleProstate international2026
Four-year outcomes of water vapor thermal therapy for benign prostatic hyperplasia.
Article in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sexual Function and Clinical Outcomes Following Rezūm Therapy for Benign Prostatic Hyperplasia: An Updated Systematic Review Including Large Prostate Volumes.Lower urinary tract symptoms · 2026Pooled it
- Factors predicting the success of ejaculation preserving transurethral resection of the prostate: a prospective cohort study.Prostate international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Rezūm system offers a minimally invasive treatment option for alleviating lower urinary tract symptoms associated with benign prostatic hyperplasia. We report the 48-month outcomes from a single tertiary center. Materials and methods: A retrospective study was conducted to review Rezūm therapy from 2021 to 2025 at our tertiary hospital. Maximum urinary flow rate, International Prostate Symptom Score, quality of life, post-void residual, prostate volume, and adverse events were actively monitored. Analyses were performed at baseline and at follow-up intervals of 3, 12, 24, 36, and 48 months. Results: Eighty-six patients (mean age of 66.7 ± 7.3 years) were assessed in our study, of whom eleven were catheter-dependent. The mean preoperative prostate size was (71.4 ± 15.6 cc). A statistically significant improvement was recorded in all voiding parameters at 3 months, including maximum urinary flow rate, International Prostate Symptom Score, quality of life, and post-void residual ( Conclusion: Rezūm therapy demonstrates both safety and efficacy in managing benign prostatic hyperplasia-related lower urinary tract symptoms, offering maximum benefit within the first 2 years after treatment. Patient selection and counseling regarding the potential need for future medical or surgical retreatment are recommended to optimize long-term outcomes and patients' satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.